Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT.

Rosenow F, Berkemeier A, Krug U, Müller-Tidow C, Gerss J, Silling G, Groth C, Wieacker P, Bogdanova N, Mesters R, Büchner T, Kienast J, Berdel WE, Stelljes M.

Bone Marrow Transplant. 2013 Aug;48(8):1070-6. doi: 10.1038/bmt.2013.2. Epub 2013 Feb 4.

PMID:
23376821
2.

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl MG, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel WE, Ehninger G, Beelen DW, Schetelig J, Stelljes M.

Lancet Oncol. 2012 Oct;13(10):1035-44. doi: 10.1016/S1470-2045(12)70349-2. Epub 2012 Sep 7.

PMID:
22959335
3.

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.

Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, Holowiecki J, Giebel S, Markiewicz M, Uharek L, Blau IW, Kienast J, Stelljes M, Larsson K, Zander AR, Gramatzki M, Repp R, Einsele H, Stuhler G, Baumgart J, Mylius HA, Pichlmeier U, Freund M, Casper J.

Haematologica. 2011 Sep;96(9):1344-50. doi: 10.3324/haematol.2011.043810. Epub 2011 Jun 9.

4.

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.

Stelljes M, Beelen DW, Braess J, Sauerland MC, Heinecke A, Berning B, Kolb HJ, Holler E, Schwerdtfeger R, Arnold R, Spiekermann K, Müller-Tidow C, Serve HL, Silling G, Hiddemann W, Berdel WE, Büchner T, Kienast J; German AML Cooperative Group (AMLCG).

Haematologica. 2011 Jul;96(7):972-9. doi: 10.3324/haematol.2011.041004. Epub 2011 Apr 1.

5.

Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein α from hematopoietic cells in a family with AML.

Stelljes M, Corbacioglu A, Schlenk RF, Döhner K, Frühwald MC, Rossig C, Ehlert K, Silling G, Müller-Tidow C, Juergens H, Döhner H, Berdel WE, Kienast J, Koschmieder S.

Leukemia. 2011 Jul;25(7):1209-10. doi: 10.1038/leu.2011.64. Epub 2011 Apr 1. No abstract available.

PMID:
21455213
6.

Principles of perioperative coagulopathy.

Innerhofer P, Kienast J.

Best Pract Res Clin Anaesthesiol. 2010 Mar;24(1):1-14. Review.

PMID:
20402166
7.

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.

Kropff M, Kienast J, Bisping G, Berdel WE, Gaschler-Markefski B, Stopfer P, Stefanic M, Munzert G.

Anticancer Res. 2009 Oct;29(10):4233-8.

8.

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.

Bisping G, Wenning D, Kropff M, Gustavus D, Müller-Tidow C, Stelljes M, Munzert G, Hilberg F, Roth GJ, Stefanic M, Volpert S, Mesters RM, Berdel WE, Kienast J.

Clin Cancer Res. 2009 Jan 15;15(2):520-31. doi: 10.1158/1078-0432.CCR-08-1612.

9.

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W.

J Clin Oncol. 2009 Jan 1;27(1):61-9. doi: 10.1200/JCO.2007.15.4245. Epub 2008 Dec 1.

PMID:
19047294
10.

Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.

Schetelig J, Bornhäuser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H, Stelljes M, Hegenbart U, Schäfer-Eckart K, Füssel M, Wiedemann B, Thiede C, Kienast J, Baurmann H, Ganser A, Kolb HJ, Ehninger G.

J Clin Oncol. 2008 Nov 10;26(32):5183-91. doi: 10.1200/JCO.2007.15.5184. Epub 2008 Sep 2.

PMID:
18768435
11.

The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.

Stelljes M, van Biezen A, Slavin S, Olavarria E, Clark RE, Nagler A, Koza V, Kienast J, Niederwieser D, de Witte T, Ruutu T; complications subcommittee of the Chronic Leukemia Working Party.

Bone Marrow Transplant. 2008 Dec;42(11):739-42. doi: 10.1038/bmt.2008.254. Epub 2008 Aug 25.

PMID:
18724394
12.

Cytogenetically normal acute myeloid leukemia.

Büchner T, Berdel WE, Kienast J.

N Engl J Med. 2008 Aug 7;359(6):651; author reply 652-3. doi: 10.1056/NEJMc081230. No abstract available.

PMID:
18687649
13.

Intestinal graft-versus-host-disease staging by video capsule endoscopy.

Meister T, Heinzow H, Bisping G, Stelljes M, Schulte B, Berdel WE, Kienast J, Domschke W, Ullerich H.

Endoscopy. 2008 Sep;40 Suppl 2:E144. doi: 10.1055/s-2007-995767. Epub 2008 Jul 16. No abstract available.

PMID:
18633870
14.

High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N; Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

J Clin Oncol. 2008 Jan 10;26(2):218-24. doi: 10.1200/JCO.2007.12.6219. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262.

PMID:
18182664
15.

Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography.

Stelljes M, Hermann S, Albring J, Köhler G, Löffler M, Franzius C, Poremba C, Schlösser V, Volkmann S, Opitz C, Bremer C, Kucharzik T, Silling G, Schober O, Berdel WE, Schäfers M, Kienast J.

Blood. 2008 Mar 1;111(5):2909-18. Epub 2007 Dec 5.

PMID:
18057227
16.

Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study.

Lorenz R, Kienast J, Otto U, Kiehl M, Schreiter D, Haertel S, Barthels M.

Blood Coagul Fibrinolysis. 2007 Sep;18(6):565-70.

PMID:
17762533
17.

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf HH, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J; Deutsche Studiengruppe Multiples Myelom,.

Br J Haematol. 2007 Aug;138(3):330-7.

PMID:
17614819
18.

Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.

Stelljes M, Specht C, Albring J, Volkmann S, Schlösser V, Pauels HG, Poremba C, Bisping G, Opitz C, Scheffold C, Silling G, Kiehl M, Berdel WE, Kienast J.

Transplantation. 2007 Feb 15;83(3):314-22.

PMID:
17297406
19.

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.

Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwäble J, Hilberg F, Roth GJ, Munzert G, Stefanic M, Steffen B, Brandts C, Müller-Tidow C, Kolkmeyer A, Büchner T, Serve H, Berdel WE.

Mol Cancer Ther. 2006 Dec;5(12):3105-12.

20.

Proteasome inhibition in multiple myeloma.

Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J.

Eur J Cancer. 2006 Jul;42(11):1623-39. Epub 2006 Jul 3. Review.

PMID:
16820291
21.

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.

Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W.

J Clin Oncol. 2006 Jun 1;24(16):2480-9. Erratum in: J Clin Oncol. 2011 Jul 1;29(19):2739.

PMID:
16735702
22.

Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin.

Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Warren BL, Opal SM; KyberSept investigators.

Thromb Haemost. 2006 May;95(5):850-6.

PMID:
16676077
23.

IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial.

Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, Ubelacker R, Buchheidt D, Behre G, Hiddemann W, Schiel X.

Crit Care Med. 2006 May;34(5):1319-25.

PMID:
16540956
24.

Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells.

Pieper M, Scheffold C, Duwe S, Rossig C, Bisping G, Stelljes M, Tedder TF, Jurgens H, Berdel WE, Kienast J.

Leukemia. 2006 Apr;20(4):729-32. No abstract available.

PMID:
16437143
25.

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety.

Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM; KyberSept Investigators.

Crit Care Med. 2006 Feb;34(2):285-92.

PMID:
16424704
26.

Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM; KyberSept investigators.

J Thromb Haemost. 2006 Jan;4(1):90-7.

27.

G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis.

Kuhlmann MT, Kirchhof P, Klocke R, Hasib L, Stypmann J, Fabritz L, Stelljes M, Tian W, Zwiener M, Mueller M, Kienast J, Breithardt G, Nikol S.

J Exp Med. 2006 Jan 23;203(1):87-97. Epub 2006 Jan 9.

28.

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.

Bornhäuser M, Kröger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl MG, Wandt H, Theuser C, Ehninger G, Zander AR; Cooperative German Transplant Study Group.

Eur J Haematol. 2006 Jan;76(1):9-17.

PMID:
16343266
29.

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.

Bisping G, Kropff M, Wenning D, Dreyer B, Bessonov S, Hilberg F, Roth GJ, Munzert G, Stefanic M, Stelljes M, Scheffold C, Müller-Tidow C, Liebisch P, Lang N, Tchinda J, Serve HL, Mesters RM, Berdel WE, Kienast J.

Blood. 2006 Mar 1;107(5):2079-89. Epub 2005 Nov 8.

PMID:
16278310
30.

Treatment of older patients with AML.

Büchner T, Berdel WE, Wörmann B, Schoch C, Haferlach T, Schnittger S, Kern W, Aul C, Lengfelder E, Schumacher A, Reichle A, Staib P, Balleisen L, Eimermacher H, Grüneisen A, Rasche H, Sauerland MC, Heinecke A, Mesters RM, Serve HL, Kienast J, Hiddemann W.

Crit Rev Oncol Hematol. 2005 Nov;56(2):247-59. Epub 2005 Oct 21. Review.

PMID:
16246568
31.

Evidence for predictive validity of blood assays to evaluate individual radiosensitivity.

Severin E, Greve B, Pascher E, Wedemeyer N, Hacker-Klom U, Silling G, Kienast J, Willich N, Göhde W.

Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):242-50. Epub 2005 Sep 22.

PMID:
16182465
32.

The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation.

Erker CG, Steins MB, Fischer RJ, Kienast J, Berdel WE, Sibrowski W, Cassens U.

Transfusion. 2005 Aug;45(8):1382-90.

PMID:
16078929
33.

Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A, Berning B, Scheffold C, Silling G, Buchner T, Neubauer A, Fauser AA, Ehninger G, Berdel WE, Kienast J; Cooperative German Transplant Study Group.

Blood. 2005 Nov 1;106(9):3314-21. Epub 2005 Jul 14.

PMID:
16020510
34.

Bortezomib in combination with dexamethasone for relapsed multiple myeloma.

Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, Kienast J.

Leuk Res. 2005 May;29(5):587-90. Epub 2005 Jan 15.

PMID:
15755512
35.

Frequent gains of the short arm of chromosome 9 in multiple myeloma with normal G-banded karyotype detected by comparative genomic hybridization.

Tchinda J, Volpert S, Kropff M, Berdel WE, Kienast J, Meinhardt F, Horst J.

Am J Clin Pathol. 2004 Dec;122(6):875-82.

PMID:
15539380
36.

Factors affecting the efficacy of peripheral blood progenitor cells collections by large-volume leukaphereses with standardized processing volumes.

Cassens U, Barth IM, Baumann C, Fischer RJ, Kienast J, Vormoor J, Sibrowski W.

Transfusion. 2004 Nov;44(11):1593-602.

PMID:
15504165
37.

Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis.

Scheffold C, Kroeger M, Zuehlsdorf M, Tchinda J, Silling G, Bisping G, Stelljes M, Buechner T, Berdel WE, Kienast J.

Leukemia. 2004 Dec;18(12):2048-50. No abstract available.

PMID:
15470491
38.

Influence of keratinocyte growth factor on clonal growth of epithelial tumor cells, lymphoma and leukemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro.

Oelmann E, Haghgu S, Kulimova E, Mesters RM, Kienast J, Herbst H, Schmitmann C, Kolkmeyer A, Serve H, Berdel WE.

Int J Oncol. 2004 Oct;25(4):1001-12.

PMID:
15375550
39.

Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.

Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, Stelljes M, Bornhaeuser M, Martin H, Scheid C, Ganser A, Zander AR, Kienast J, Ehninger G, Hoelzer D, Diehl V, Fauser AA, Ringden O.

J Clin Oncol. 2004 Jul 15;22(14):2816-25.

PMID:
15254049
40.

Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions.

Steins MB, Padró T, Schwaenen C, Ruiz S, Mesters RM, Berdel WE, Kienast J.

Blood Coagul Fibrinolysis. 2004 Jul;15(5):383-91.

PMID:
15205586
41.

Transplantation strategies in AML: AMLCG data.

Kienast J, Stelljes M, Berning B, Kröger M, Sauerland MC, Heinecke A, Schoch C, Wörmann B, Büchner T, Hiddemann W, Berdel WE; German AML Cooperative Group.

Ann Hematol. 2004;83 Suppl 1:S136-7.

PMID:
15124707
42.

Subgroup specific therapy effects in AML: AMLCG data.

Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Balleisen L, Grüneisen A, Aul C, Lengfelder E, Hehlmann R, Kern W, Serve HL, Mesters RM, Eimermacher H, Frickhofen N, Kienast J, Giagounidis A, Sauerland MC, Heinecke A; German AMLCG.

Ann Hematol. 2004;83 Suppl 1:S100-1. No abstract available.

PMID:
15124694
43.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.

Stelljes M, Strothotte R, Pauels HG, Poremba C, Milse M, Specht C, Albring J, Bisping G, Scheffold C, Kammertoens T, Oelmann E, Silling G, Berdel WE, Kienast J.

Blood. 2004 Aug 15;104(4):1210-6. Epub 2004 Apr 15.

PMID:
15090450
44.

The German competence network 'Acute and chronic leukemias'.

Hehlmann R, Berger U, Aul C, Büchner T, Döhner H, Ehninger G, Ganser A, Gökbuget N, Hoelzer D, Uberla K, Gassmann W, Ludwig WD, Rieder H, Kneba M, Hochhaus A, Reiter A, Hiddemann W, Ottmann OG, Germing U, Adelhard K, Dugas M, Dirschedl P, Messerer D, Böhme A, Harrison-Neu E, Griesshammer M, Kienast J, Kolb HJ, Ho AD, Hallek M, Neubauer A, Schlegelberger B, Niederwieser D, Heil G, Müller T, Hasford J.

Leukemia. 2004 Apr;18(4):665-9. No abstract available.

PMID:
15044925
45.

c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions.

Kienast J, Berdel WE.

Cancer Cell. 2004 Feb;5(2):109-10. Review.

46.

Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia.

Bieker R, Padró T, Kramer J, Steins M, Kessler T, Retzlaff S, Herrera F, Kienast J, Berdel WE, Mesters RM.

Cancer Res. 2003 Nov 1;63(21):7241-6.

47.

Thalidomide for the treatment of acute myeloid leukemia.

Steins MB, Bieker R, Padró T, Kessler T, Kienast J, Berdel WE, Mesters RM.

Leuk Lymphoma. 2003 Sep;44(9):1489-93. Review.

PMID:
14565649
48.

Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Einsele H, Bertz H, Beyer J, Kiehl MG, Runde V, Kolb HJ, Holler E, Beck R, Schwerdfeger R, Schumacher U, Hebart H, Martin H, Kienast J, Ullmann AJ, Maschmeyer G, Krüger W, Niederwieser D, Link H, Schmidt CA, Oettle H, Klingebiel T; Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Ann Hematol. 2003 Oct;82 Suppl 2:S175-85. Epub 2003 Sep 10.

PMID:
13680165
49.

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.

Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M, Mitterer M, Südhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel WE, Kienast J.

Br J Haematol. 2003 Aug;122(4):607-16.

PMID:
12899716
50.

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group.

J Clin Oncol. 2003 Jul 15;21(14):2747-53.

PMID:
12860954

Supplemental Content

Loading ...
Support Center